Updated:
Syntec Optics Holdings
Founded in 1989, Syntec Optics built its initial reputation supplying precision polymer optics for Eastman Kodak's copier and photographic lines in...
Syntec Optics Holdings
Founded in 1989, Syntec Optics built its initial reputation supplying precision polymer optics for Eastman Kodak's copier and photographic lines in Rochester, New York. Under Chairman and CEO Al Kapoor, who acquired control in 1997, the company pivoted away from consumer imaging into defense, biomedical, and instrumentation markets. The transition was powered by proprietary high-precision diamond-turning processes and injection-molding capabilities that allow the firm to manufacture complex aspheric and freeform lenses at scale. The underlying wealth or family-office structure is not publicly detailed; the firm operates as a publicly traded manufacturing company (Nasdaq: OPTX) following its business combination with OmniLit Acquisition Corp. in November 2022. Syntec's strategy concentrates on vertically integrated polymer-optics manufacturing — from design engineering and tooling to production of finished assemblies — for defense, medical, and industrial-sensing end markets. Confirmed active programs include optical components for night-vision goggle systems (per the firm's 2022 investor presentation), ophthalmic surgical devices, and precision sensor lenses for autonomous platforms. The company runs its operations across two adjacent facilities in Rochester totaling approximately 100,000 square feet. Geographically, Syntec serves North American and European customers, with defense contractors and medical-device OEMs constituting the bulk of its book. The firm does not operate as a fund or pool outside capital; it uses its public-company balance sheet to invest in capital equipment and automation. Since its 2022 public listing, Syntec has disclosed approximately $22 million in trailing annual revenue with a workforce of roughly 120 employees (per 10-K, 2023). Adjacent vehicles include no known philanthropic foundations or private-investment arms; the entity itself is the operating company. In August 2023, Syntec announced a multi-year production contract for advanced optical assemblies used in U.S. Army night-vision systems (per Syntec Optics, August 2023), reinforcing its position as a qualified second-source supplier for legacy military optics platforms. Syntec's structure as a publicly listed, pure-play precision-optics contract manufacturer sets it apart from both the large defense primes that dominate the sector and the privately held custom-optics shops that serve niche scientific markets. That public-company posture forces disclosure and provides a transparent window into a traditionally opaque U.S. defense supply chain — a rare structural differentiator for allocators tracking domestic reshoring and industrial-mobilization themes.
General information
Firm type
Asset Manager
Year founded
1989
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Rochester
Corporate office
Rochester, NY, United States
Principals
Al Kapoor
Chairman and CEO
Joe Mohr
CTO
Sara Hart
CFO
Sector focus
Frequently asked questions
Who runs investment and operational decisions at Syntec Optics?
Chairman and CEO Al Kapoor has led Syntec since acquiring the business in 1997 and is the principal decision-maker for capital allocation and operational strategy. CTO Joe Mohr oversees the technical roadmap, including diamond-turning and injection-molding process development. CFO Sara Hart manages financial operations and public-company reporting following the 2022 Nasdaq listing.
How does Syntec Optics source its revenue?
Syntec generates revenue primarily through long-term manufacturing contracts with Tier-1 defense prime contractors and medical-device OEMs. The company positions itself as a vertically integrated partner — doing its own design engineering, tooling, production, and assembly in Rochester — rather than as a commodity lens supplier. Its sales pipeline is built on repeat production programs for legacy military platforms and next-generation surgical devices where requalification costs create switching barriers.
Is Syntec Optics structured as a family office or an operating company?
Syntec is an operating company, not a family office or investment fund. It became publicly traded on Nasdaq under ticker OPTX in November 2022 via a SPAC merger with OmniLit Acquisition Corp. The firm does not manage outside capital or function as an allocator; it deploys its cash flow into manufacturing equipment, automation, and facilities within its precision-optics business.
Which end markets does Syntec Optics serve?
Syntec serves three primary end markets: defense (night-vision optics, targeting systems, aerospace sensors), biomedical (ophthalmic surgical devices, diagnostic instrumentation), and industrial sensing (autonomous-vehicle LIDAR components, machine-vision lenses). Defense and medical constitute the largest share, with exposure to U.S. Army night-vision programs and FDA-regulated surgical-device supply chains.
What is Syntec's relationship to the legacy Eastman Kodak optics supply chain?
Syntec launched in 1989 as a supplier to Kodak's copier and camera divisions during Kodak's peak as Rochester's largest employer. When that consumer-imaging volume declined in the late 1990s and early 2000s, Syntec repurposed its precision molding and diamond-turning capabilities for defense and medical markets. The firm's Rochester location and workforce still draw on the skilled optics-labor pool that Kodak and Xerox built over decades in the region.
Does Syntec Optics maintain any investment or philanthropic vehicles separate from the operating company?
No separate philanthropic or private-investment vehicles are publicly disclosed. Syntec operates as a single entity — a publicly traded manufacturer — and does not appear to sponsor a foundation, family-office arm, or co-investment vehicle.
What is Syntec's known posture on co-investment or partnerships with external GPs?
Syntec is not an allocator or LP in external funds; it does not engage in co-investment alongside GPs. Its partnerships are commercial manufacturing relationships — primarily with defense primes and medical-device OEMs — not financial co-investment structures. The firm's public-company balance sheet is the sole investment vehicle.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: